期刊文献+

高效液相色谱法测定奥沙利铂注射液中奥沙利铂的含量和有关物质 被引量:6

Oxaliplatin Determination of Oxaliplatin Injection Liquid by High Performance Liquid Chromatography
下载PDF
导出
摘要 建立以高效液相色谱法测定奥沙利铂注射液中的奥沙利铂有关物质和含量的方法,以碳十八烷基硅烷键合硅胶为填充剂,规格250mm×4.6mm,粒径5μm,以水-甲醇(90∶10)为流动相,流动相用0.45μm的膜过滤,紫外检测波长为250nm。奥沙利铂在50~1600μg/ml的浓度范围内,峰面积与浓度呈线性关系,线性曲线方程为A=3650.9C+17.095(r=0.9999),最低检测限为1.2ng。加样平均回收率为99.4%(RSD=0.81%,n=9)。本方法简便、灵敏、准确,可用于奥沙利铂注射液中的有关物质和含量的控制。 To establish the determination method of related substances and content of oxaliplatin injection by high performance liquid chromatography(HPLC). HPLC is performed to determine octadecylsilyl silica gel chromatography column,250 mm × 4.6 mm,diameter 5 μ m,The mobile phase is methanol-water(10:90),mobile phase by 0.45 μm membrane filter,the detecting wavelength is 250 nm. The detected concentration of oxaliplatin is in the good linear range of 50~1 600 μg/ml (r=1.000 0),the limit of detection is 1.2 ng,and the average recovery is 99.4%(RSD=0.81%,n=9). The established method is simple,sensitive,accurate and available for the quality control of oxaliplatin.
出处 《东华理工大学学报(自然科学版)》 CAS 2010年第3期290-292,共3页 Journal of East China University of Technology(Natural Science)
关键词 高效液相色谱法 奥沙利铂 有关物质 含量测定 high performance liquid chromatography oxaliplatin related substances content assay
  • 相关文献

参考文献6

二级参考文献25

  • 1张文,许立功.晚期结直肠癌的化疗进展[J].中国癌症杂志,2004,14(4):378-382. 被引量:25
  • 2任鹏,孙坚彤,沈云玉,黄彩英.反相高效液相色谱法测定奥沙利铂的含量[J].抗感染药学,2005,2(1):24-24. 被引量:17
  • 3胡发明.奥沙利铂的不良反应和安全性[J].国外医药合成药·生化药·制剂分册,1999,20(3):184-185.
  • 4[3]Missct JL.Oxaliolatinin practice[J].Br J Cancer,1998,77(Suppl 4):S4~S7.
  • 5Richard H, Wilson, Tanya Lehky, et al.Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability[J] .J Clin Oncol,2002,20(7):1767 - 1774.
  • 6Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
  • 7Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
  • 8Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
  • 9Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.
  • 10Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspeets[J]. Clin Pharmacokinet,2000,38(1) : 1 - 21.

共引文献122

同被引文献50

  • 1王小林,林根来,龚高全,陈颐,张峰,艾松涛.阿霉素磁性白蛋白纳米微粒介入治疗兔VX2肝肿瘤[J].复旦学报(医学版),2004,31(4):383-386. 被引量:8
  • 2张文,许立功.晚期结直肠癌的化疗进展[J].中国癌症杂志,2004,14(4):378-382. 被引量:25
  • 3杨明莉,武凯,鲜学福.金属-有机络合聚合物(MOCPs)的研究进展[J].功能材料,2006,37(11):1697-1699. 被引量:6
  • 4Ibrahim A, Hirschfeld S, Cohen MH. FDA drug approval summaries : oxaliplatin[J]. Oncologist, 2004,9( 1 ) : 8.
  • 5Anderson NH, Blundell R, Brown S, et al. Formulations : WO 99/43355[P].1999-09-02.
  • 6乌桑·易卜拉欣,罗朗一伊夫·莫维耐.一种药学上稳定的奥沙利铂制剂:瑞士,CN95194443.6[P].1997-07-16.
  • 7Faang J, Nakamura H, Maeda H. The EPR effecunique features of tumor blood vessels for drug delivery, factors involved,and limitations and augmentation of the effect[J]. Adv Drug Deliv Rev,2011,63(3):136-151.
  • 8Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect[J]. Adv Drug Deliv Rev,2011,63(3) : 170-183.
  • 9Yang C, Liu HZ, Fu ZX, et al. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma [J]. BMC Biotechnol, 2011,11:21.
  • 10Abu Lila AS, Kizuki S, Doi Y, et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual targeting approach in a murine solid tumor model[J]. J Control Release,2009,137(1) :8-14.

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部